Blueprint
FORM 6-K
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
Report
of Foreign Issuer
Pursuant
to Rule 13a-16 or 15d-16 of
the
Securities Exchange Act of 1934
For the
month of September 2016
Commission
File Number: 001-11960
AstraZeneca PLC
1
Francis Crick Avenue
Cambridge
Biomedical Campus
Cambridge
CB2 0AA
United
Kingdom
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F X
Form
40-F __
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(1):
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(7): ______
Indicate
by check mark whether the registrant by furnishing the information
contained in this Form is also thereby furnishing the information
to the Commission pursuant to Rule 12g3-2(b) under the Securities
Exchange Act of 1934.
Yes __ No
X
If
“Yes” is marked, indicate below the file number
assigned to the Registrant in connection with Rule
12g3-2(b): 82-_____________
28 September 2016 07:00
CHANGE TO ASTRAZENECA BOARD OF DIRECTORS
AstraZeneca
today announced that Dr Cornelia (Cori) Bargmann, a Non-Executive
Director, will step down from the Board of AstraZeneca PLC and as a
member of the Company's Science Committee with effect from 1
October 2016. Dr Bargmann recently accepted a new position as
President of Chan Zuckerberg Science, part of the Chan Zuckerberg
Initiative.
Leif
Johansson, AstraZeneca Chairman, said: "We congratulate Cori on her
new appointment and thank her for her contribution to AstraZeneca
in the last 18 months. We are sorry to see her leave the
AstraZeneca Board but fully understand her decision to step down to
focus on her new assignment."
About AstraZeneca
AstraZeneca is a global, science-led biopharmaceutical company that
focuses on the discovery, development and commercialisation of
prescription medicines, primarily for the treatment of diseases in
three therapy areas - Respiratory and Autoimmunity, Cardiovascular
and Metabolic Diseases, and Oncology.
The Company is also active in inflammation, infection and
neuroscience through numerous collaborations. AstraZeneca operates
in over 100 countries and its innovative medicines are used by
millions of patients worldwide. For more information please
visit: www.astrazeneca.com
CONTACTS
|
Media Enquiries
|
|
|
|
Neil
Burrows
|
UK/Global
|
+44 203
749 5637
|
|
Vanessa
Rhodes
|
UK/Global
|
+44 203
749 5736
|
|
Karen
Birmingham
|
UK/Global
|
+44 203
749 5634
|
|
Rob
Skelding
|
UK/Global
|
+44 203
749 5821
|
|
Jacob
Lund
|
Sweden
|
+46 8
553 260 20
|
|
Michele
Meixell
|
US
|
+1 302
885 2677
|
|
Investor Relations
|
|
|
|
UK
|
|
|
|
Thomas
Kudsk Larsen
|
|
+44 203
749 5712
|
|
Craig
Marks
|
Finance,
Fixed Income, M&A
|
+44
7881 615 764
|
|
Nick
Stone
|
Respiratory
& Autoimmunity
|
+44 203
749 5716
|
|
Henry
Wheeler
|
Oncology
|
+44 203
749 5797
|
|
Christer
Gruvris
|
Infection
& Neuroscience
|
+44 203
749 5711
|
|
US
|
|
|
|
Lindsey
Trickett
|
Cardiovascular
& Metabolic Diseases
|
+1 240
543 7970
|
|
Mitchell
Chan
|
Oncology
|
+1 240
477 3771
|
|
Toll-free
|
|
+1 866
381 7277
|
Adrian
Kemp
Company
Secretary
AstraZeneca
PLC
-ENDS-
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
AstraZeneca
PLC
Date:
28 September
2016
By: /s/
Adrian Kemp
Name:
Adrian Kemp
Title:
Company Secretary